PD-L1 (E1L3N®) XP® Rabbit mAb #13684
产品特性
| 产品货号： | 13684 |
| 规格： | 20 μL; 100 μL |
| 物种免疫 ： | 兔 |
| 同种型： | IgG |
| 克隆性： | 单克隆 |
| 免疫原： | 使用与人 PD-L1 蛋白中羧基末端周围的残基相对应的合成肽，对动物进行免疫接种来产生单克隆抗体。 |
| 种属反应性： | 人 |
| 特异性/灵敏度： | PD-L1 (E1L3N®) XP® Rabbit mAb 可识别内源水平的 PD-L1 总蛋白。 |
| 应用： | 蛋白质印迹法 1:1000 |
| 免疫沉淀法 1:50 | |
| IHC Leica BOND 1:200 – 1:800 | |
| 免疫组织化学（石蜡） 1:100 – 1:400 | |
| 流式细胞术（固定/通透） 1:200 – 1:800 | |
| 保存： | 保存在 10 mM sodium HEPES (pH 7.5)、150 mM NaCl、100 µg/ml BSA、50% 甘油和低于 0.02% 的叠氮化钠中。-20℃ 保存。切勿分装抗体。 |
靶标信息
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410).
As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410).
Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410).
The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity).
The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
产品来源
Cell Signaling Technology
